All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2020-10-02T09:28:06.000Z

New Drug Application submitted for belumosudil to FDA

Oct 2, 2020
Share:

Bookmark this article

A submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) was made for the Rho-associated coiled coil kinase 2 (ROCK2) inhibitor belumosudil (KD025) for the treatment of patients with chronic graft-versus−host disease (cGvHD). The NDA will be reviewed under the Real-Time Oncology Review pilot program.1 The FDA has previously granted belumosudil a Breakthrough Therapy designation for patients with relapsed/refractory cGvHD, which was reported on by the GvHD Hub and can be found here.

This submission comes after the results of the ROCKstar phase II trial (NCT03640481), in which 132 patients, who had received ≥ 2 lines of prior therapies were treated with 200 mg of belumosudil, either once or twice daily. The primary endpoint was overall response rate. At 6 months, overall response rates of 73% and 74% were achieved in the single- and double-daily dose groups, respectively, and responses were maintained for ≥ 20 weeks in 49% of responders. No unexpected adverse events were witnessed; common severe adverse events consistied of dyspnea, GGT increase, hyperglycemia, anemia, and lung infections. The GvHD Hub reported on the positive topline results from this trial earlier this year, and these can be found here.

Belumosudil is a ROCK2-specific inhibitor that binds to and inhibits the serine/threonine kinase activity. This results in inhibition of ROCK2-mediated signaling pathways and effects the inflammatory cell responses.

  1. Kadmon. Kadmon announces submission of New Drug Application to the U.S. FDA for belumosudil in patients with chronic graft-versus-host disease. https://www.accesswire.com/608562/Kadmon-Announces-Submission-of-New-Drug-Application-to-the-US-FDA-for-Belumosudil-in-Patients-with-Chronic-Graft-Versus-Host-Disease. Published Sep 30, 2020. Accessed Oct 1, 2020.

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox